Tag Archives: NYSE:DB

Analysts’ Perspective: FactSet (FDS), Catalent (CTLT), Deutsche Bank (DB)

FactSet Research Systems Inc. (NYSE:FDS) shares were upgraded by analysts at Northcoast from Neutral to Buy rating.

FactSet Research Systems Inc. engages in the provision of financial information and analytical applications.

*

Brokerage Firm Morgan Stanley upgraded Catalent Inc. (NYSE:CTLT) shares from Equal-Weight to Overweight rating.

Catalent, Inc. is a holding company, which engages in the research, development and marketing of pharmaceutical products.

*

Investment Analysts at HSBC Securities upgraded Deutsche Bank AG (NYSE:DB) shares from Reduce to Hold rating.

Deutsche Bank AG engages in the provision of corporate banking and investment services.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/

Analysts’ View: Kroger (KR), Deutsche Bank (DB), Inovalon (INOV)

Investment Analysts at Pivotal Research Group upgraded Kroger Co. (NYSE:KR) shares from Hold to Buy rating.

The Kroger Co. engages in the operation of retail food and drug stores, multi-department stores, jewelry stores, and convenience stores.

*

Brokerage Firm Keefe Bruyette upgraded Deutsche Bank AG (NYSE:DB) shares from Market Perform to Outperform rating.

Deutsche Bank AG engages in the provision of corporate banking and investment services.

*

Inovalon Holdings, Inc. (NASDAQ:INOV) shares were upgraded by analysts at Morgan Stanley from Underweight to Equal-Weight rating.

Inovalon Holdings, Inc. engages in the provision of cloud-based platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/